These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26825901)

  • 21. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
    Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
    Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostacyclin for pulmonary hypertension.
    Paramothayan NS; Lasserson TJ; Wells AU; Walters EH
    Cochrane Database Syst Rev; 2003; (2):CD002994. PubMed ID: 12804447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostacyclin in the intensive care setting.
    Ivy DD
    Pediatr Crit Care Med; 2010 Mar; 11(2 Suppl):S41-5. PubMed ID: 20216163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy of severe pulmonary hypertension with prostacyclin and iloprost].
    Matthes J; Mathen F; Herzig S; Wassermann K
    Dtsch Med Wochenschr; 2001 May; 126(21):631-7. PubMed ID: 11413752
    [No Abstract]   [Full Text] [Related]  

  • 25. Prostanoids for pulmonary arterial hypertension.
    Galiè N; Manes A; Branzi A
    Am J Respir Med; 2003; 2(2):123-37. PubMed ID: 14720012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beraprost therapy for pulmonary arterial hypertension.
    Barst RJ; McGoon M; McLaughlin V; Tapson V; Rich S; Rubin L; Wasserman K; Oudiz R; Shapiro S; Robbins IM; Channick R; Badesch D; Rayburn BK; Flinchbaugh R; Sigman J; Arneson C; Jeffs R;
    J Am Coll Cardiol; 2003 Jun; 41(12):2119-25. PubMed ID: 12821234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
    McLaughlin VV; Palevsky HI
    Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost-A Multicentre, Retrospective Study.
    Camara RP; Coelho FDN; Cruz-Martins N; Marques-Alves P; Castro G; Baptista R; Ferreira F
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostanoids for intermittent claudication.
    Robertson L; Andras A
    Cochrane Database Syst Rev; 2013 Apr; (4):CD000986. PubMed ID: 23633305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
    Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
    Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhalation of repurposed drugs to treat pulmonary hypertension.
    Gessler T
    Adv Drug Deliv Rev; 2018 Aug; 133():34-44. PubMed ID: 29886070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of treprostinil in the management of pulmonary hypertension.
    Skoro-Sajer N; Lang I
    Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience.
    Sitbon O; Vonk Noordegraaf A
    Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28096285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?
    El Yafawi R; Wirth JA
    Curr Hypertens Rep; 2017 Oct; 19(12):97. PubMed ID: 29071454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension.
    He B; Zhang F; Li X; Tang C; Lin G; Du J; Jin H
    Circ J; 2010 Jul; 74(7):1458-64. PubMed ID: 20519876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A
    BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experiences with treprostinil in the treatment of pulmonary arterial hypertension.
    Stream AR; Bull TM
    Ther Adv Respir Dis; 2012 Oct; 6(5):269-76. PubMed ID: 22868690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostacyclin for pulmonary hypertension in adults.
    Paramothayan NS; Lasserson TJ; Wells AU; Walters EH
    Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD002994. PubMed ID: 15846646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
    Wang S; Yu M; Zheng X; Dong S
    Drug Deliv; 2018 Nov; 25(1):1898-1909. PubMed ID: 30442035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.
    Hoeper MM; Taha N; Bekjarova A; Gatzke R; Spiekerkoetter E
    Eur Respir J; 2003 Aug; 22(2):330-4. PubMed ID: 12952269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.